In sarcoma immunoradiotherapy, elevated tumour‐associated macrophages (TAMs) expressing IL4I1/HES1 predict poor response, highlighting the need for combinatorial approaches targeting monocyte–macrophage axes [40]. The gene discussed is IL4I1; the disease is neoplasm.